Abstract
Methotrexate is transported into the cell by the reduced folate carrier (RFC) and out of the cell by members of the multidrug resistance protein family (MRP). Transport proteins may affect the therapeutic efficacy of this drug in patients with rheumatoid arthritis. To investigate the potential benefit of the presence of RFC and the absence of functional MRP for the efficacy of methotrexate treatment. The study involved 163 patients (116 female, 47 male; mean age 59.5 years) on methotrexate (mean weekly dose 12.2 mg). RFC was determined using reverse transcriptase polymerase chain reaction, and MRP function by flow cytometry, using a calcein acetoxymethylesther/probenecid assay. Clinical response to methotrexate was evaluated by the EULAR response criteria and the ACR 20% improvement criteria. The clinical data were obtained at the beginning of methotrexate treatment and at the time of blood sampling during ongoing therapy. Patients were divided into four groups according to the presence (+) or absence (-) of RFC and functional (f) MRP. fMRP+/RFC+ and fMRP-/RFC- patients more often had good EULAR response rates (60%, p = 0.014, and 53%, p = 0.035, respectively) in comparison with the fMRP-/RFC+ group (29%); fMRP+/RFC- patients h...Continue Reading
References
Jan 1, 1990·Annual Review of Nutrition·G B Henderson
Dec 1, 1988·Zhonghua nei ke za zhi·J L Yang
Mar 1, 1988·Arthritis and Rheumatism·F C ArnettH S Luthra
Mar 28, 1985·The New England Journal of Medicine·M E WeinblattD E Trentham
Dec 30, 1983·The American Journal of Medicine·R T Hoffmeister
Jun 1, 1995·Arthritis and Rheumatism·D T FelsonV Strand
Jan 1, 1996·Arthritis and Rheumatism·A M van GestelP L van Riel
May 30, 1998·Biochemical Pharmacology·S C WongL H Matherly
Aug 26, 1998·Rheumatic Diseases Clinics of North America·J M Kremer
Aug 14, 1999·Arthritis and Rheumatism·N Nakashima-MatsushitaT Matsuyama
Oct 8, 1999·Arthritis and Rheumatism·K YudohT Kimura
Jul 21, 2000·Arthritis and Rheumatism·P RahmanD Robb
Aug 17, 2000·Journal of the National Cancer Institute·P BorstJ Wijnholds
Feb 13, 2001·Biochemical and Biophysical Research Communications·D MaJ A Moscow
Mar 10, 2001·Life Sciences·B LaupèzeO Fardel
Apr 27, 2001·Toxicology Letters·D SchrenkH M Kauffmann
Jul 24, 2001·Arthritis and Rheumatism·A E van EdeL B van de Putte
Aug 14, 2001·The Journal of Biological Chemistry·K ItoS P Cole
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Xavier DeclèvesJean-Michel Scherrmann
Dec 18, 2002·The Journal of Biological Chemistry·Yehuda G AssarafGerrit Jansen
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Maciej J Zamek-GliszczynskiKim L R Brouwer
Sep 27, 2003·Biochemical and Biophysical Research Communications·Jungil HongChung S Yang
Citations
Jan 13, 2009·Clinical Rheumatology·V AgarwalR Misra
Jan 5, 2007·Nature Clinical Practice. Rheumatology·Joost W van der HeijdenGerrit Jansen
Mar 1, 2006·Annals of the Rheumatic Diseases·S L HiderI N Bruce
May 19, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Jean-Francis MaillefertUNKNOWN Réseau Rhumato Study Group
Sep 17, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Azza A K El-SheikhFrans G M Russel
Dec 31, 2015·Diagnostic Pathology·Tamás MicsikIstván Peták
Jan 28, 2006·Mayo Clinic Proceedings·Carl Turesson, Eric L Matteson
Apr 17, 2014·International Journal of Rheumatic Diseases·Shiva PrasadVikas Agarwal
Feb 28, 2015·Immunopharmacology and Immunotoxicology·Lorena Michele Brennan-BourdonJosé Francisco Muñoz-Valle
Feb 28, 2009·Arthritis and Rheumatism·Joost W van der HeijdenGerrit Jansen
Mar 14, 2018·Inflammopharmacology·Mary Beth YuWilliam H R Langridge
Aug 7, 2020·Inflammopharmacology·Jun Yu, Peng Zhou
Jan 12, 2021·Life Sciences·Jinzhang GaoWei Wei